Ogilvy to promote Lundbeck's antidepressant drug vortioxetine

Ogilvy's health team has won a global brief to help launch a drug mooted as a 'breakthrough treatment' for depression.

Depression specialist: Lundbeck’s headquarters in Denmark
Depression specialist: Lundbeck’s headquarters in Denmark

Lundbeck, a pharma firm that specialises in brain disorders, has appointed Ogilvy PR Health as the global agency for vortioxetine, its first new antidepressant in five years.

The agency will provide comms around its launch in all markets except the US. The brief includes medical and media comms, data dissemination and stakeholder management.

Comms around the launch in the US will be handled by Lundbeck’s commercial partner, Japanese pharma firm Takeda.

Vortioxetine is considered a ‘multimodal’ antidepressant, which means it is thought to work across a range of neurotransmitters, or signal-transmitting chemicals found in the brain.

The company hopes it will be more effective than many current antidepressants that act mainly on one type, such as serotonin.

Business unit head Joanne Wunder, who is leading on the account, said: ‘We are excited about the potential of vortioxetine because there is still significant unmet need in the area of depression. Many patients need to try two or more antidepressants before finding one that works for them.’

The drug is also seen as significant in ensuring the company’s future growth, as another antidepressant cipralex – for which Ogilvy also does global brand comms – is coming off patent protection.

Vortioxetine was submitted to EU and US regulators for approval in September and October this year.

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus

Latest Articles

The latest social media fail case study: #myNYPD

The latest social media fail case study: #myNYPD

The NYPD's Twitter fail offers another social media lesson for organisations.

Edelman US chief Mark Hass steps down

Former top lobbyist and H&K CEO Robert Gray passes away at 92

Former top lobbyist and H&K CEO Robert Gray passes away at 92

Robert Gray, an influential Washington, DC, lobbyist and former chairman and CEO of Hill & Knowlton, passed away last Friday. He was 92.

Max Clifford trial jury to reconvene tomorrow after majority verdicts direction

Max Clifford trial jury to reconvene tomorrow after majority verdicts direction

The jury in the trial of celebrity publicist Max Clifford on 11 charges of indecent assault has been sent home for the day after being told by the judge earlier this afternoon that he will now accept majority verdicts.